glp-1 drugs heart failure Could medications be helpful for your heart? Our experts weigh in on the potential benefits and side effects of the popular weight loss medications Impact of glp-1 receptor agonists
Description
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Looking Ahead As the market evolves, stakeholders are watching for regulatory updates and court decisions that could reshape the boundaries of compounding
Modern prescription weight loss medications: Wegovy, Ozempic, Mounjaro, Zepbound.
The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans, pharmacy chains, and the federal government.
